Closing the Biosimilar Adoption Gap Through Transparent PBM Contracting

Closing the Biosimilar Adoption Gap Through Transparent PBM Contracting

Executive Summary

Specialty drugs are projected to exceed 60 percent of pharmacy spend in 2026 while accounting for fewer than 5 percent of prescriptions.1 Biosimilars offer employers one of the most direct sources of relief: several adalimumab biosimilars carry wholesale acquisition costs (WAC) 85 to 86 percent below that of Humira.2 Yet the savings that reach a self-funded plan depend less on whether a biosimilar exists than on how the plan’s pharmacy benefit manager (PBM) contract allocates rebates, classifies drugs, and sets member cost sharing.

Two developments now give plan sponsors greater leverage. First, the Consolidated Appropriations Act, 2026 (CAA 2026), signed on February 3, 2026, requires PBMs to pass through 100 percent of rebates and related remuneration to ERISA plans for plan years beginning on or after August 3, 2028 (January 1, 2029, for calendar-year plans). It also subjects PBMs to ERISA compensation disclosure rules.3,4 Second, the Federal Trade Commission (FTC) has reached settlements with Express Scripts and Caremark that bar each PBM from disadvantaging lower list price versions of a drug on its standard formularies, and it has withdrawn its case against Optum Rx from adjudication to consider a proposed consent agreement.5,6

For HR benefit leaders and CHROs, renewals negotiated over the next two years will set the terms under which these reforms take effect. Sponsors that pair transparent contracting with a Biosimilar First formulary strategy, member cost sharing aligned with net cost, and documented fiduciary oversight will be best positioned to capture savings and to demonstrate prudence.

The Specialty Spend Problem

Pharmaceutical Strategies Group (PSG) reported specialty trend of 12.5 percent net of rebates in 2025, with net cost reaching $1,251 per member per year, and projects gross per member costs to rise another 32 percent by 2028. Utilization drove nearly all of that trend, as the share of members using a specialty drug rose from 4.4 percent in 2023 to 5.5 percent in 2025.7

Biosimilar competition is working in some categories. PSG data show overall biosimilar share rising from 22.6 percent in 2023 to 56.3 percent in 2025, with adalimumab biosimilars reaching 82.4 percent.8 That outcome was not automatic. In 2023, their first year on the U.S. market, adalimumab biosimilars captured less than 2 percent of the market despite discounts greater than 80 percent.9 Share moved only after the largest PBMs changed their formulary strategies, and the same design choices will determine results for ustekinumab, denosumab, aflibercept, and the molecules that follow.

Three Structural Barriers to Biosimilar Savings

1. Formulary Economics Built on Rebates

Under traditional PBM arrangements, manufacturers compete for preferred formulary placement through rebates calculated from list price, and PBMs may retain a share of those rebates or collect fees tied to list price. The FTC alleged that this system led the three largest PBMs to place high list price, high rebate insulin products on standard formularies while excluding lower list price versions with comparable net prices.5 The same incentive applies to biologics, because a low-WAC biosimilar generates little rebate. PSG researchers have observed that rebating and PBM formulary strategies can blunt expected biosimilar savings.8

Private label biosimilars marketed through PBM affiliates add complexity. One such arrangement raised the WAC of its adalimumab products, while another kept its biosimilar at a consistently low WAC.10 Sponsors should therefore evaluate net cost per claim rather than assume that any biosimilar on formulary delivers the expected discount.

2. Patent Thickets and Delayed Entry

Goode and Chao found that, on average, nine times more patents were steered away from biosimilars in the United States than in Canada, twelve times more than in the United Kingdom, and that U.S. launches followed approval more slowly.11 Their review of the U.S. Humira portfolio found that roughly 80 percent of its patents were not patentably distinct from one another. The FDA approved the first adalimumab biosimilar in 2016, and biosimilars were sold in Europe from 2018, yet U.S. competition did not begin until 2023.9,12 Etanercept shows the same pattern: two approved biosimilars remain barred from the U.S. market until 2029.12 For benefit planning, launch timing is set by litigation and settlement, not by FDA approval alone.

3. Provider Reimbursement and Regulatory Friction

Reimbursement drives prescribing behavior. For physician administered biologics, reimbursement based on a percentage of drug price can reward use of the higher cost product. A study in JAMA Network Open found that biosimilar entry reduced Medicare Part B originator prices more than simple before and after comparisons suggest, yet the savings remained below those achieved by small molecule generics; the authors identify the percentage-based reimbursement model as a likely contributor.13 Employers face similar incentives under the medical benefit.

Regulatory barriers are easing. In June 2024, the FDA issued draft guidance proposing that switching studies generally will not be needed to demonstrate interchangeability.14 In October 2025, it proposed that comparative efficacy studies may often be unnecessary to demonstrate biosimilarity.15 Both remain in draft guidance.

Traditional and Transparent PBM Models Compared

PBM Contract Model Comparison
Contract Feature Traditional Model Transparent Model
Pricing Spread pricing: the plan is billed more than the PBM pays the pharmacy, and the PBM keeps the difference Pass-through pricing: the plan pays the pharmacy reimbursement amount with no retained spread
Rebates PBM may retain a portion of manufacturer rebates and fees; amounts are often undisclosed 100 percent of rebates and related remuneration remitted to the plan and reconciled quarterly
Biosimilar Strategy Placement may favor products that generate larger rebates; low-WAC biosimilars can be disadvantaged Lowest net cost product preferred; low-WAC biosimilars such as Hadlima, Yusimry, and Simlandi eligible for preferred status
Medical Benefit Drugs Limited visibility into infused drug costs and site of care markups Claims level reporting that supports site of care and markup review
PBM Compensation Varies with list price, volume, and rebate retention Disclosed flat administrative fee, per member or per employee per month

 

Employer demand is shifting. In a 2025 survey of 324 employers, 31 percent reported a transparent PBM as their primary PBM, up from 12 percent in 2024, while use of the three largest PBMs fell from 72 percent to 61 percent.16 Transparency alone does not guarantee savings, however. As revenue tied to list price declines, sponsors should expect PBMs to seek new administrative or service fees,17 which makes fee definitions and audit rights central to any contract.

The ERISA Fiduciary Imperative

The Consolidated Appropriations Act (CAA 2026) converts several terms that sponsors previously had to negotiate into federal requirements. The provisions most relevant to self-funded plan sponsors are summarized below:

  • Rebate pass-through. PBMs must remit 100 percent of rebates, fees, alternative discounts, and other remuneration from manufacturers, group purchasing organizations, and rebate aggregators each quarter, no later than ninety days after quarter end. Reasonable fees for bona fide services remain permitted if they are transparent and quantifiable.18
  • Covered service provider status. PBMs must disclose direct and indirect compensation under ERISA Section 408(b)(2). Absent further Department of Labor guidance, this change is presumed effective for contracts entered into or renewed on or after February 3, 2026.3
  • Audit rights. At least once per plan year, the plan may audit rebate records, including rebate contracts, using an auditor the plan fiduciary selects. The PBM may not pay for the auditor, directly or indirectly.18
  • Reporting. Plans with 100 or more participants receive semiannual reports by drug covering spread pricing, rebates, formulary rationale, and affiliated pharmacies.3
  • Penalties. Civil penalties reach $10,000 per day for failure to disclose and up to $100,000 for knowingly providing false information.19

A PBM contract that does not provide full pass-through will not be considered reasonable under ERISA Section 408(b)(2), which exposes the arrangement to prohibited transaction risk.19,20 The statute’s innocent fiduciary exception may protect a fiduciary who did not know of a PBM’s failure to remit, demanded remittance in writing, and notified the Department of Labor if the PBM did not comply within ninety days. The exception does not eliminate the general duties of prudence and monitoring.3 The Department of Labor has also proposed PBM disclosure regulations for self-insured ERISA plans.19 Because ERISA makes fiduciaries personally liable for plan losses that result from a breach (29 U.S.C. § 1109), CHROs who serve on benefits committees should ensure that PBM oversight is documented with the same rigor applied to retirement plan fee reviews.

Under the FTC settlements, Express Scripts and Caremark must offer standard options that allow plans to move away from rebate guarantees and spread pricing and to pass rebates to members at the point of sale, but plans are not required to adopt them.21 Core requirements take effect by January 1, 2028; Optum Rx settlement terms had not been published in the reports reviewed.6,17

An Operational Framework for Plan Sponsors

Optimatum recommends the following sequence for sponsors with a renewal or market check in the next contract cycle.

Phase 1: Diagnostic Audit (Weeks 1 to 4)

  • Obtain complete pharmacy and medical claims data directly, rather than relying on summary portal reports.
  • Identify reference biologic claims for which a biosimilar is licensed using the FDA Purple Book, noting molecules such as etanercept whose approved biosimilars are not yet marketed.22
  • Restate each specialty claim to net cost after rebates and compare the results with independent benchmarks to estimate retained spread and rebate leakage.

Phase 2: Procurement and Formulary Redesign (Weeks 5 to 8)

  • Issue a request for proposal that prohibits spread pricing, requires 100 percent rebate pass-through with quarterly reconciliation, and specifies a disclosed flat administrative fee.
  • Define rebates consistently with the scope of CAA 2026, including fees and remuneration from manufacturers, group purchasing organizations, and rebate aggregators.
  • Adopt a Biosimilar First protocol for molecules with marketed biosimilars, such as adalimumab, infliximab, and ustekinumab, that prefers the lowest net cost product and includes clinical exception criteria.

Phase 3: Plan Design and Governance (Weeks 9 to 12 and Ongoing)

  • Set member cost sharing for preferred biosimilars at or below that of the reference product, so that members are not penalized for choosing the lower cost option.
  • Charter a benefits committee that includes the CHRO, CFO, and General Counsel to review PBM performance, fees, and audit findings annually.
  • Seek contract language under which the PBM accepts fiduciary responsibility for its discretionary functions, and record the outcome of that negotiation in the selection file.

Essential Contract Provisions

Standard PBM templates favor the PBM. Optimatum recommends the following provisions in any new or renewed agreement.

  • Comprehensive rebate definition. Rebates should include all manufacturer and intermediary remuneration, including data fees, administrative fees, and fees tied to price inflation, with 100 percent pass-through, quarterly reconciliation, and a cure obligation for any shortfall identified at audit.
  • Classification tied to FDA registries. Generic, brand, biologic, and biosimilar status should follow the FDA Orange Book and Purple Book,22,23 so that proprietary classification cannot alter pricing guarantees, tier placement, or rebate calculations.
  • Unrestricted audit rights. The plan should select its auditor, define audit scope, and audit at least annually without PBM approval of methodology, consistent with the CAA 2026 prohibition on PBM payment for the auditor.18
  • Settlement option review. Express Scripts and Caremark clients should evaluate the low-WAC formulary and point of sale rebate options required under the FTC settlements before the January 1, 2028, implementation date.17

Conclusion

CAA 2026 and the FTC settlements change the baseline for PBM contracting, but neither delivers savings automatically: settlement options apply only when a plan elects them,21 and pass-through governs where rebates go, not which drugs a formulary prefers. The employers that benefit most will audit and benchmark the pharmacy benefit and align formulary and member cost sharing with net cost.

Optimatum Solutions provides independent PBM contract audits, transparent procurement, and fiduciary governance support. Organizations that wish to quantify their savings opportunity are invited to contact our advisory team for a diagnostic assessment.

References

  1. Drug Topics. 2026. “Specialty Drug Costs and Complexity Steadily Rising Since 2025.” July 2026.
  2. AJMC. 2025. “Biosimilar Market Share: Growth and Price Trends in Q1 2025.” American Journal of Managed Care.
  3. Morgan Lewis. 2026. “Consolidated Appropriations Act of 2026: The New Landscape of PBM Fiduciary Oversight.” February 2026.
  4. Stanton, Timothy J., Ryan B. Kadevari, and Oyinade O. Adebayo. 2026. “PBM Reforms May Open a New Era for Group Health Plan Sponsors.” Ogletree Deakins, March 5, 2026.
  5. FTC (Federal Trade Commission). 2026. “FTC Secures Major Settlement with Caremark, Resolving Antitrust Case Against Second Drug Middleman.” Press release, July 14, 2026.
  6. Healthcare Dive. 2026. “UnitedHealth, FTC Reach Proposed Settlement in Insulin Case.” June 12, 2026.
  7. Pharmaceutical Strategies Group. 2026. “2026 State of Specialty Spend and Trend.” Press release, July 2026.
  8. Managed Healthcare Executive. 2026. “PSG: Specialty Drug Spending Predicted to Increase 32% by 2028.” July 2026.
  9. Association for Accessible Medicines. 2024. The U.S. Generic & Biosimilar Medicines Savings Report 2024. Washington, DC: Association for Accessible Medicines, September.
  10. Center for Biosimilars. 2025. “Biosimilars Drive Cost Savings and Achieve 53% Market Share Across Treatment Areas.” January 16, 2025.
  11. Goode, Rachel, and Bernard Chao. 2022. “Biological Patent Thickets and Delayed Access to Biosimilars, an American Problem.” Journal of Law and the Biosciences 9 (2): lsac022.
  12. Center for Biosimilars. 2021. “Sandoz Is 0-3 in Enbrel Patent Case.” May 17, 2021.
  13. Abdelaziz, Abdullah, Aaron N. Winn, Stacie B. Dusetzina, and Aaron P. Mitchell. 2025. “Biologic Drug Prices in Medicare Part B After Entry of Biosimilars to the Market.” JAMA Network Open 8 (11): e2542937.
  14. FDA (U.S. Food and Drug Administration). 2024. “FDA Updates Guidance on Interchangeability.” June 20, 2024.
  15. FDA (U.S. Food and Drug Administration). 2025. “FDA Moves to Accelerate Biosimilar Development and Lower Drug Costs.” Press release, October 29, 2025.
  16. National Alliance of Healthcare Purchaser Coalitions. 2025. Pulse of the Purchaser 2025 Annual Survey. September 2025.
  17. Truveris. 2026. “FTC Settlements with ESI, CVS, and Optum Rx.” July 2026.
  18. Mintz. 2026. “Congress Passes Landmark PBM Reform in 2026 Spending Bill.” February 6, 2026.
  19. NFP. 2026. “Federal PBM Reform Is Finally Law.” February 2026.
  20. Groom Law Group. 2026. “Drug Pricing and Plan Contracting Practices Under Scrutiny: PBM and TPA Reforms in the Consolidated Appropriations Act, 2026.” February 10, 2026.
  21. Mintz. 2026. “FTC Reaches Second Insulin Pricing Settlement: Comparing the Caremark and ESI Orders.” July 17, 2026.
  22. FDA (U.S. Food and Drug Administration). n.d. “Purple Book: Database of Licensed Biological Products.” Accessed November 10, 2026.
  23. FDA (U.S. Food and Drug Administration). n.d. “Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.” Accessed November 10, 2026.